Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer
| العنوان: | Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer |
|---|---|
| المؤلفون: | Ryo Ariyasu, Noriko Yanagitani, Fumiyoshi Ohyanagi, Ken Uchibori, Tsukasa Hasegawa, Makoto Nishio, Keita Kudo, Shingo Nishikawa, Yuichi Tambo, Atsushi Horiike, Satoru Kitazono |
| المصدر: | International Journal of Clinical Oncology. 26:507-514 |
| بيانات النشر: | Springer Science and Business Media LLC, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, medicine.medical_specialty, Bevacizumab, business.industry, Phases of clinical research, Combination chemotherapy, Hematology, General Medicine, medicine.disease, Chemotherapy regimen, Gastroenterology, 03 medical and health sciences, Regimen, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Internal medicine, medicine, Mucositis, Surgery, business, Adverse effect, Lung cancer, medicine.drug |
| الوصف: | We assessed the efficacy and safety of bevacizumab and S-1 chemotherapy for patients with previously treated advanced non-squamous non-small-cell lung cancer (NSCLC). This was a prospective single-arm study, including patients with non-squamous NSCLC who had received at least one chemotherapy regimen along with a platinum-based regimen. Bevacizumab 15 mg/kg was intravenously administered every 3 weeks, and S-1 40 mg/m2 was orally administered twice daily from day 1 (evening) through day 15 (morning). The treatment continued for 3 weeks/cycle until disease progression or until unacceptable toxicities occurred. During the lead-in part, six patients were evaluated for dose-limiting toxicity (DLT) rate. In phase II, the primary endpoint was objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and safety. In the lead-in part, we evaluated the safety in the first six patients and observed no DLT. In phase II, a total of 46 patients were enrolled from September 2012 to December 2018. The median follow-up duration was 13.7 months [95% confidence interval (CI) 1.4–72.0]. The ORR was 28.3%. The median PFS and OS were 4.3 (95% CI 2.9–5.9) and 15.0 months (95% CI 9.8–30.3), respectively. The most common adverse events were hypertension (65.2%), diarrhea (47.8%), mucositis oral (45.7%), and proteinuria (43.5%), and the most common grade 3 adverse events were hypertension (23.9%) and proteinuria (6.5%). Grade 4/5 adverse events were not observed. Bevacizumab and S-1 combination chemotherapy showed high activity and were well tolerated in patients with previously treated advanced non-squamous NSCLC. |
| تدمد: | 1437-7772 1341-9625 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::6d6f784915f0cfcebc80ffafd4cfc39dTest https://doi.org/10.1007/s10147-020-01822-7Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi...........6d6f784915f0cfcebc80ffafd4cfc39d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14377772 13419625 |
|---|